Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334153 | 1.00 | KIF11 (0.35) | KIF11SCDHDAC1HDAC2MAPT | |
| SCHEMBL3334713 | 0.84 | KIF11 (0.38) | KIF11HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL3331881 | 0.81 | KIF11 (0.33) | KIF11 | |
| SCHEMBL3331883 | 0.81 | KIF11 (0.33) | KIF11 | |
| SCHEMBL3330466 | 0.75 | KIF11 (0.34) | KIF11HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL3330470 | 0.75 | KIF11 (0.34) | KIF11HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL3329349 | 0.73 | KDM4E (0.35) | KIF11MAPTKMT2A | |
| SCHEMBL3329351 | 0.73 | KDM4E (0.35) | KIF11MAPTKMT2A | |
| SCHEMBL3334313 | 0.72 | KIF11 (0.33) | KIF11MAPT | |
| SCHEMBL3332597 | 0.72 | KIF11 (0.36) | KIF11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344154-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MARUYAMA TAKAHISA | 2010-06-10 | — | — | US | disclosed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, TPMT | KIF11 3795/4885SCD 764/4885HDAC1 440/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | KIF11 4452/4885SCD 491/4885HDAC1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.